Non-Cystic Fibrosis Bronchiectasis (NCFB) Market to Exhibit Substantial Growth by 2032, Estimates DelveInsight | Key Companies – Zambon, Novartis, Insmed, Aradigm Corporation, and Others

Delveinsight Business Research LLP
DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Non-Cystic Fibrosis Bronchiectasis (NCFB) market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Non-Cystic Fibrosis Bronchiectasis (NCFB): An Overview

Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. Non‐cystic fibrosis bronchiectasis often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease.

The prevalence of NCFB is reported to be higher in females. The prevalence of NCFB varies among populations, but studies report an overall prevalence ranging from 486 to 1106 per 100,000 persons with an incidence that appears to be rising, particularly in women and older individuals.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Key Facts

As per DelveInsight’s estimates, in 2018, the prevalence of Non–cystic fibrosis bronchiectasis was estimated to be 812,260+ in the 7MM.

The United State accounted for the most prevalent cases of Non–cystic fibrosis bronchiectasis among 7MM with 447,000+ cases in 2018.

Among EU5 countries, Germany had the highest number of prevalent cases of Non–cystic fibrosis bronchiectasis accounting for 45,600+ cases in 2018. 

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market

The Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Size in the 7MM was found to be USD 1,218 Million in 2018. The market size shall increase during the forecast period owing to the launch of upcoming therapies in the 7MM. Extensive research and development activities of pharmaceutical companies will also significantly impact market growth.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Non-Cystic Fibrosis Bronchiectasis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Non-Cystic Fibrosis Bronchiectasis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology

The epidemiology section covers insights into the historical and current Non-Cystic Fibrosis Bronchiectasis patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Segmentation

Prevalent Population of NCFB

Diagnosed Population of NCFB

Etiology associated with NCFB 

Microbiology of NCFB patients

Gender-Specific Diagnosed Prevalence of NCFB

Severity Specific Diagnosed prevalence NCFB

Non-Cystic Fibrosis Bronchiectasis (NCFB) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Cystic Fibrosis Bronchiectasis market or expected to get launched in the market during the study period. The analysis covers Non-Cystic Fibrosis Bronchiectasis market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Non-Cystic Fibrosis Bronchiectasis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Non-Cystic Fibrosis Bronchiectasis (NCFB) Therapeutics Analysis

The Non‐Cystic Fibrosis Bronchiectasis market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, and incremental healthcare spending across the world.

Key companies in the Non-Cystic Fibrosis Bronchiectasis Market include:




Aradigm Corporation 

And others.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Therapies covered in the report include:


Colistimethate sodium

Ciprofloxacin dispersion for inhalation 

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Non-Cystic Fibrosis Bronchiectasis (NCFB) Competitive Intelligence Analysis

4. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Overview at a Glance

5. Non-Cystic Fibrosis Bronchiectasis (NCFB) Disease Background and Overview

6. Non-Cystic Fibrosis Bronchiectasis (NCFB) Patient Journey

7. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology and Patient Population

8. Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Cystic Fibrosis Bronchiectasis (NCFB) Unmet Needs

10. Key Endpoints of Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment

11. Non-Cystic Fibrosis Bronchiectasis (NCFB) Marketed Products

12. Non-Cystic Fibrosis Bronchiectasis (NCFB) Emerging Therapies

13. Non-Cystic Fibrosis Bronchiectasis (NCFB) Seven Major Market Analysis

14. Attribute Analysis

15. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Outlook (7 major markets)

16. Non-Cystic Fibrosis Bronchiectasis (NCFB) Access and Reimbursement Overview

17. KOL Views on the Non-Cystic Fibrosis Bronchiectasis (NCFB) Market.

18. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Drivers

19. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Other Latest Reports By DelveInsight

Food Allergy Market

DelveInsight’s “Food Allergy Market” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology, as well as the Food Allergy Market Trends in the 7MM. Some of the key companies in the Food Allergy Market include Aimmune Therapeutics, Novartis, DBV Technologies, InnoUp Farma, Cour Pharmaceutical Development Company, Vedanta Biosciences, Regeneron Pharmaceuticals, Genentech, Rho Federal Systems Division, Alladapt Immunotherapeutics, Camallergy, and Others.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States